PAG
TVTX icon

Private Advisor Group’s Travere Therapeutics TVTX Stock Holding History

Private Advisor Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$706K Sell
12,422
-3,000
-19% -$133K ﹤0.01% 1558
2026
Q1 		$458K Buy
15,422
+3,010
+24% +$90K ﹤0.01% 1921
2025
Q4 		$474K Buy
+12,412
New +$404K ﹤0.01% 1855

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's TVTX Position: Q2 2026 in Review

Private Advisor Group reduced its Travere Therapeutics (TVTX) stake by 19% in Q2 2026, selling an estimated $133K and leaving 12,422 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #1558.

Private Advisor Group first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Private Advisor Group held 12,422 shares of Travere Therapeutics worth $706K as of Q2 2026.
  • Private Advisor Group sold 3,000 Travere Therapeutics shares in Q2 2026, an estimated $133K.
  • Travere Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #1558 holding.
  • Private Advisor Group first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.